Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Bioventus Inc. regarding breaches of fiduciary duties by its board of directors following a class action complaint related to the company's IPO and subsequent financial disclosures [1]. Company Overview - Bioventus is a medical device company focused on developing and commercializing clinical treatments that enhance the body's natural healing process [2]. IPO Details - Bioventus conducted its IPO on February 11, 2021, issuing 8 million shares of Class A common stock at an offering price of $13.00 per share [3]. Allegations of Misconduct - The Offering Documents were alleged to be negligently prepared, containing untrue statements and omissions that misled investors about the company's financial health and operations [4]. - Specific allegations include significant liquidity issues, unsustainable rebate practices, and deficient internal controls over financial reporting [4]. Financial Reporting Issues - On November 16, 2022, Bioventus announced it could not timely file its quarterly report due to a decline in market capitalization and the need to assess potential non-cash impairment charges [5]. - The company later disclosed a non-cash impairment charge of $189.2 million and changes to its historical practices regarding rebate recognition, impacting its ability to meet debt covenants [6]. Stock Performance - Following the financial disclosures, Bioventus's stock price fell significantly, closing at $1.97 per share on November 17, 2022, a decline of 33.67% from the previous day [5]. - By November 22, 2022, the stock price further declined to $1.81 per share, representing an overall decline of 86.08% from the IPO price [7]. Investor Impact - The wrongful acts and omissions by the defendants have resulted in significant losses for investors, as the market value of Bioventus's securities has drastically decreased [8].

Core Viewpoint - Bioventus Inc. will report its financial results for Q2 of fiscal year 2024 on August 6, 2024, and will host a conference call to discuss these results and provide a business update [3]. Group 1: Financial Reporting - The financial results for the second quarter of fiscal year 2024 will be announced before the market opens on August 6, 2024 [3]. - A conference call is scheduled for 8:30 a.m. Eastern Time on the same day to discuss the results [3]. Group 2: Company Overview - Bioventus is a global leader in innovations for active healing, focusing on clinically proven and cost-effective products that aid in quick and safe healing [5]. - The company's mission is to help patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [5]. - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [5].

To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. About Bioventus Investor and Media Inquiries: Dave Crawford 919-474-6787 Dave.Crawford@bioventus.com DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market opens on Tuesday, August 6, ...

Bioventus (BVS) makes minimally invasive treatments that engage and enhance the body's natural healing process. Bioventus is focusing on accelerating top-line growth, enhancing operational efficiency and improving profitability, cash flow, and liquidity. Its medical products are focused on three segments — Pain Treatments, Restorative Therapies and Surgical Solutions. It is seeing double-digit revenue growth in both Pain Treatments and Surgical Solutions, which has improved its profitability. It delivered 1 ...

Finding good prospects is like hunting gold in the fast-paced world of investing. Three stocks stand out in this hunt, all under $10, with significant growth potential. These companies operate in a variety of industries, including technology and healthcare. They offer a unique opportunity to profit from rapid revenue growth, strong financial stability and well-thought-out development strategies. With a robust organic revenue increase in the first quarter and a solid focus on the hyaluronic acid (HA) busines ...

Chase Knickerbocker - Craig-Hallum Robbie Marcus - JPMorgan Chase & Co. Caitlin Cronin - Canaccord Genuity Thank you, Andrea, and good morning, everyone, and thanks for joining us. It is my pleasure to welcome you to the Bioventus 2024 first-quarter earnings conference call. With me this morning are Rob Claypoole, President and CEO; and Mark Singleton, Senior Vice President and CFO. Rob will begin his remarks with an update on our 2024 priorities in our business. Mark will provide detail of our first-quarte ...

Exhibit 99.1 DURHAM, NC – May 7, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 30, 2024. First Quarter 2024 Financial Results: *See below under "Use of Non-GAAP Financial Measures" for more details. The following table represents net sales by geographic region, and by business, for the three months ended March 30, 2024 and April 1, 2023: (a) Sales from the SonicOne produ ...

DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 a ...

Financial Performance - Q4 2023 - Revenue increased by 8% to $135 million compared to the prior year quarter[26] - Pain Treatments revenue increased 23% compared to prior year[27] - Surgical Solutions revenue grew 12%[27] - Adjusted EBITDA increased by $5 million to $22 million compared to the prior year quarter[26] - Adjusted gross margin increased 20 basis points to 71.4%[30, 31] Financial Position - Debt outstanding is $395 million[35] - Cash balance at the end of the quarter is $37 million[50] 2024 Financial Guidance - Expect net sales to be in the range of $520 million to $535 million[51] - Expect adjusted EBITDA to be in the range of $89 million to $94 million[37] Strategic Initiatives - Accelerating revenue growth, especially in Ultrasonics with double-digit growth expected[7] - Prioritizing funding initiatives and re-allocating resources to maximize return[7] - Improving operational efficiency and reducing expenses related to integrations and debt restructuring[18] - Organic revenue growth increased 14% compared to the prior year quarter when adjusting for the divestiture of Wound Business[21]

Bioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET Company Participants Dave Crawford - Vice President, Investor Relations Rob Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Caitlin Cronin d - Canaccord Genuity Operator Good day, and welcome to the Bioventus Inc. Fourth Quarter 2023 Earnings Conference Call. [Operator Instruct ...